While substantial strides have been made against some types of childhood cancers, high-grade gliomas still lack effective treatments.
Around 30% to 60% percent of these paediatric brain tumours bear mutations in the gene H3F3A. This gene contains the encoded blueprint for histone H3.3, which plays an important role in the structure of chromatin.
One of these mutations is known to scientists as H3.3G34R/V, meaning the amino acid glycine that’s normally found at position 34 has been replaced by either an arginine or a valine.
Now an international research team led by the University of Michigan Health Rogel Cancer Center has found a small-molecule inhibitor that was able to suppress tumour growth in animal models of this glioma, offering new hope toward developing therapies for paediatric patients.
Their findings appear in Science Translational Medicine.
“These tumours tend to occur in slightly older children than some of the more well-known types of childhood glioma, usually between the ages of 10 and 18,” said senior study author Sriram Venneti, M.D., Ph.D., the Al and Robert Glick Family Research Professor of Paediatrics in the Department of Pathology at Michigan Medicine.
“And the prospects remain quite dismal due to a lack of effective treatments.”
Led by first author Stefan Sweha, a graduate student in neuroscience, the team investigated epigenetic changes to the tumours, that is, changes that are not permanent mutations to the DNA itself, but which affect how cells access and read DNA sequences.
Ultimately, they found alterations that led to increased secretion of a protein known as LIF, for leukaemia inhibitory factor. LIF, in turn, activates the STAT3 signalling pathway, which has been implicated in a number of other types of cancer.
In mouse models of H3.3G34R/V glioma, a small-molecule inhibitor of STAT3 called WP1066 was shown to suppress tumour growth and greatly improve how long the mice survived.
The drug compound has the important property of being able to cross the blood-brain barrier, which is critical for developing brain cancer treatments, and is currently being tested in clinical trials for glioblastoma in adult patients, Venneti adds.
“Our goal is to move the compound into clinical trials for paediatric patients,” he said.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.